Alkalinization Using Sodium Bicarbonate for COVID-19 Treatment: A Systematic Review and Meta-Analysis.

IF 3.3 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Evidence-based Integrative Medicine Pub Date : 2024-01-01 DOI:10.1177/2515690X241258403

Arman Shafiee, Kyana Jafarabady, Hassan Moltazemi, Mohammad Javad Amini, Mohammad Ali Rafiei, Amirhossein Akhondi, Sayed-Hamidreza Mozhgani

{"title":"Alkalinization Using Sodium Bicarbonate for COVID-19 Treatment: A Systematic Review and Meta-Analysis.","authors":"Arman Shafiee, Kyana Jafarabady, Hassan Moltazemi, Mohammad Javad Amini, Mohammad Ali Rafiei, Amirhossein Akhondi, Sayed-Hamidreza Mozhgani","doi":"10.1177/2515690X241258403","DOIUrl":null,"url":null,"abstract":"Background: A systematic review and meta-analysis have been conducted to evaluate the efficacy of alkalinization for COVID-19 patients based on current evidence to determine the impact of alkalinization on COVID-19 outcomes.Methods: We searched MEDLINE (Pubmed), Web of Science, Cochrane Library, and Clinicaltrials.gov for studies evaluating the efficacy of alkalinization up to 30 April 2023. Based on the PRISMA 2020 statement criteria a systematic review and meta-analysis of studies were performed.Results: The results of our meta-analysis showed a significant reduction in mortality rate in the alkalinization group compared to controls (RR 0.73, 95% CI: 0.56-0.95; I2 = 0%). However, our subgroup analysis showed no significant improvement in RCT-only studies (RR 0.78, 95% CI: 0.59-1.05; I2 = 0%), the recovery rate was significantly higher in the alkalinization group (RR 2.13, 95% CI: 1.39-3.26; I2 = 0%), duration of recovery also has improved in alkalinization group (SMD 0.76, 95% CI: 0.33-1.18; I2 = 0%). The results of our meta-analysis showed a significant reduction in the duration of hospitalization in the alkalinization group compared to controls with very low certainty of evidence (SMD -0.66, 95% CI: -0.97 to -0.35; I2 = 36%).Conclusion: With low certainty of evidence, alkalinization (by sodium bicarbonate) can be an efficient and safe adjuvant treatment for COVID-19 patients. Future randomized controlled trials are needed to strengthen the available evidence.","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145993/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Evidence-based Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2515690X241258403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: A systematic review and meta-analysis have been conducted to evaluate the efficacy of alkalinization for COVID-19 patients based on current evidence to determine the impact of alkalinization on COVID-19 outcomes.

Methods: We searched MEDLINE (Pubmed), Web of Science, Cochrane Library, and Clinicaltrials.gov for studies evaluating the efficacy of alkalinization up to 30 April 2023. Based on the PRISMA 2020 statement criteria a systematic review and meta-analysis of studies were performed.

Results: The results of our meta-analysis showed a significant reduction in mortality rate in the alkalinization group compared to controls (RR 0.73, 95% CI: 0.56-0.95; I2 = 0%). However, our subgroup analysis showed no significant improvement in RCT-only studies (RR 0.78, 95% CI: 0.59-1.05; I2 = 0%), the recovery rate was significantly higher in the alkalinization group (RR 2.13, 95% CI: 1.39-3.26; I2 = 0%), duration of recovery also has improved in alkalinization group (SMD 0.76, 95% CI: 0.33-1.18; I2 = 0%). The results of our meta-analysis showed a significant reduction in the duration of hospitalization in the alkalinization group compared to controls with very low certainty of evidence (SMD -0.66, 95% CI: -0.97 to -0.35; I2 = 36%).

Conclusion: With low certainty of evidence, alkalinization (by sodium bicarbonate) can be an efficient and safe adjuvant treatment for COVID-19 patients. Future randomized controlled trials are needed to strengthen the available evidence.

查看原文本刊更多论文

使用碳酸氢钠碱化治疗 COVID-19：系统回顾与元分析》。

背景：我们进行了一项系统综述和荟萃分析，根据目前的证据评估对 COVID-19 患者进行碱化治疗的疗效，以确定碱化治疗对 COVID-19 结果的影响：我们检索了 MEDLINE (Pubmed)、Web of Science、Cochrane Library 和 Clinicaltrials.gov 中截至 2023 年 4 月 30 日的评估碱化疗效的研究。根据 PRISMA 2020 声明标准，对研究进行了系统回顾和荟萃分析：荟萃分析结果显示，与对照组相比，碱化组的死亡率显著降低（RR 0.73，95% CI：0.56-0.95；I2 = 0%）。然而，我们的亚组分析表明，在仅有 RCT 的研究中没有明显改善（RR 0.78，95% CI：0.59-1.05；I2 = 0%），碱化组的康复率明显更高（RR 2.13，95% CI：1.39-3.26；I2 = 0%），碱化组的康复持续时间也有所改善（SMD 0.76，95% CI：0.33-1.18；I2 = 0%）。我们的荟萃分析结果显示，与对照组相比，碱化组的住院时间显著缩短，但证据的确定性很低（SMD -0.66，95% CI：-0.97 至 -0.35；I2 = 36%）：在证据确定性较低的情况下，对 COVID-19 患者进行碱化（使用碳酸氢钠）是一种高效、安全的辅助治疗方法。未来需要进行随机对照试验来加强现有证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Evidence-based Integrative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

15 weeks